Literature DB >> 20635186

The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism.

Tommaso Bovi1, Angelo Antonini, Sarah Ottaviani, Angela Antonioli, Maria Paola Cecchini, Vincenzo Di Francesco, Maria Antonietta Bassetto, Mauro Zamboni, Antonio Fiaschi, Giuseppe Moretto, Andrea Sbarbati, Francesco Osculati, Michele Tinazzi.   

Abstract

Olfactory impairment has been reported in drug-induced parkinsonism (DIP), but the relationship between dopaminergic dysfunction and smell deficits in DIP patients has not been characterized. To this end, we studied 16 DIP patients and 13 patients affected by Parkinson's disease (PD) using the "Sniffin' Sticks" test and [(123)I] FP-CIT SPECT (single-photon emission computed tomography). DIP patients were divided based on normal (n = 9) and abnormal (n = 7) putamen dopamine transporter binding. Nineteen healthy age- and sex-matched subjects served as controls of smell function. Patients with DIP and pathological putamen uptake had abnormal olfactory function. In this group of patients, olfactory TDI scores (odor threshold, discrimination and identification) correlated significantly with putamen uptake values, as observed in PD patients. By contrast, DIP patients with normal putamen uptake showed odor functions-with the exception of the threshold subtest-similar to control subjects. In this group of patients, no significant correlation was observed between olfactory TDI scores and putamen uptake values. The results of our study suggest that the presence of smell deficits in DIP patients might be more associated with dopaminergic loss rather than with a drug-mediated dopamine receptor blockade. These preliminary results might have prognostic and therapeutic implications, as abnormalities in these individuals may be suggestive of an underlying PD-like neurodegenerative process.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20635186     DOI: 10.1007/s00415-010-5631-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  28 in total

1.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

2.  Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis.

Authors:  G Tissingh; H W Berendse; P Bergmans; R DeWaard; B Drukarch; J C Stoof; E C Wolters
Journal:  Mov Disord       Date:  2001-01       Impact factor: 10.338

3.  Multicenter investigation of 1,036 subjects using a standardized method for the assessment of olfactory function combining tests of odor identification, odor discrimination, and olfactory thresholds.

Authors:  G Kobal; L Klimek; M Wolfensberger; H Gudziol; A Temmel; C M Owen; H Seeber; E Pauli; T Hummel
Journal:  Eur Arch Otorhinolaryngol       Date:  2000       Impact factor: 2.503

4.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

Authors:  L Farde; A L Nordström; F A Wiesel; S Pauli; C Halldin; G Sedvall
Journal:  Arch Gen Psychiatry       Date:  1992-07

5.  Neuroleptic-induced parkinsonism is associated with olfactory dysfunction.

Authors:  Stephanie Krüger; Antje Haehner; Claudia Thiem; Thomas Hummel
Journal:  J Neurol       Date:  2008-09-03       Impact factor: 4.849

6.  Prevalence of smell loss in Parkinson's disease--a multicenter study.

Authors:  A Haehner; S Boesveldt; H W Berendse; A Mackay-Sim; J Fleischmann; P A Silburn; A N Johnston; G D Mellick; B Herting; H Reichmann; T Hummel
Journal:  Parkinsonism Relat Disord       Date:  2009-01-11       Impact factor: 4.891

Review 7.  DAT imaging in drug-induced and psychogenic parkinsonism.

Authors:  Eduardo Tolosa; Miguel Coelho; Marisol Gallardo
Journal:  Mov Disord       Date:  2003-10       Impact factor: 10.338

8.  [123I]FP-CIT SPET imaging in drug-induced Parkinsonism.

Authors:  Michele Tinazzi; Sarah Ottaviani; Ioannis U Isaias; Isabella Pasquin; Maria Steinmayr; Claudio Vampini; Manuela Pilleri; Giuseppe Moretto; Antonio Fiaschi; Nicola Smania; Piergiorgio Giorgetti; Angelo Antonini
Journal:  Mov Disord       Date:  2008-10-15       Impact factor: 10.338

9.  Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration.

Authors:  R L Doty; D A Deems; S Stellar
Journal:  Neurology       Date:  1988-08       Impact factor: 9.910

10.  Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism.

Authors:  Michele Tinazzi; Angelo Antonini; Tommaso Bovi; Isabella Pasquin; Maria Steinmayr; Giuseppe Moretto; Antonio Fiaschi; Sarah Ottaviani
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

View more
  10 in total

1.  Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.

Authors:  Stanley N Caroff; Irene Hurford; Janice Lybrand; E Cabrina Campbell
Journal:  Neurol Clin       Date:  2011-02       Impact factor: 3.806

2.  Influence of intranasal exposure of MPTP in multiple doses on liver functions and transition from non-motor to motor symptoms in a rat PD model.

Authors:  Indrani Datta; S R Mekha; Alka Kaushal; Kavina Ganapathy; Rema Razdan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-08-29       Impact factor: 3.000

Review 3.  Olfactory Dysfunction as an Early Biomarker in Parkinson's Disease.

Authors:  Michelle E Fullard; James F Morley; John E Duda
Journal:  Neurosci Bull       Date:  2017-08-22       Impact factor: 5.203

Review 4.  Olfaction in Parkinson's disease and related disorders.

Authors:  Richard L Doty
Journal:  Neurobiol Dis       Date:  2011-12-20       Impact factor: 5.996

Review 5.  Olfactory loss as a supporting feature in the diagnosis of Parkinson's disease: a pragmatic approach.

Authors:  Katie Hoyles; Jagdish C Sharma
Journal:  J Neurol       Date:  2013-02-03       Impact factor: 4.849

6.  Clinical Features Indicating Nigrostriatal Dopaminergic Degeneration in Drug-Induced Parkinsonism.

Authors:  Seung Ha Lee; Han Kyeol Kim; Young Gun Lee; Chul Hyoung Lyoo; Sung Jun Ahn; Myung Sik Lee
Journal:  J Mov Disord       Date:  2016-12-27

7.  Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer's disease dementia.

Authors:  Thomas G Beach; Charles H Adler; Nan Zhang; Geidy E Serrano; Lucia I Sue; Erika Driver-Dunckley; Shayamal H Mehta; Edouard E Zamrini; Marwan N Sabbagh; Holly A Shill; Christine M Belden; David R Shprecher; Richard J Caselli; Eric M Reiman; Kathryn J Davis; Kathy E Long; Lisa R Nicholson; Anthony J Intorcia; Michael J Glass; Jessica E Walker; Michael M Callan; Javon C Oliver; Richard Arce; Richard C Gerkin
Journal:  PLoS One       Date:  2020-04-22       Impact factor: 3.240

8.  Gait abnormalities and non-motor symptoms predict abnormal dopaminergic imaging in presumed drug-induced Parkinsonism.

Authors:  Whitley W Aamodt; Jacob G Dubroff; Gang Cheng; Betty Taylor; Stephanie Wood; John E Duda; James F Morley
Journal:  NPJ Parkinsons Dis       Date:  2022-04-28

Review 9.  Recognition and Management of Antipsychotic-Induced Parkinsonism in Older Adults: A Narrative Review.

Authors:  Sharadha Wisidagama; Abiram Selladurai; Peter Wu; Marco Isetta; Jordi Serra-Mestres
Journal:  Medicines (Basel)       Date:  2021-05-26

10.  Olfaction in patients with Parkinson's disease: a new threshold test analysis through turning points trajectories.

Authors:  Maria Paola Cecchini; Elisa Mantovani; Angela Federico; Alice Zanini; Sarah Ottaviani; Carla Masala; Michele Tinazzi; Stefano Tamburin
Journal:  J Neural Transm (Vienna)       Date:  2021-07-30       Impact factor: 3.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.